Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012 : Market Research Report

Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012

Published: Nov. 1, 2005 - 91 Pages

List of Tables
List of Figures
Executive Summary: Objectives of the Report; Research Methodology
Chapter 1 Introduction to Mood Disorders and Cognitive Impairment: Depression; Prevalence; Aetiology of Depression; Types of Depression; Major depression; Dysthymia; Bipolar Disorder; Symptoms of Depression; Anxiety Disorders; Prevalence; Cognitive Impairments and Memory Deficits; Prevalence; Pharmacotherapy for Cognitive Impairment
Chapter 2 The Global Market for Mood Disorders: Depression and Anxiety: Mood Disorders: Depression and Anxiety; Market Overview of Drugs to Treat Depression and Anxiety Disorders; Market Analysis and Insights for Drugs to Treat Depressive Illnesses; Market Analysis: Antidepressant Therapy Area; Prozac (Fluoxetine) - Eli Lilly; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Cymbalta (Duloxetine) - Eli Lilly/Boehringer Ingelheim; Product Overview; Indications and Supplementary Labelling; Sales Prospects; Commercial Outlook; Zoloft/Lustral (Sertraline) - Pfizer; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Seroxat/Paxil/Deroxat (Paroxetine) - GlaxoSmithKline; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Wellbutrin (Bupropion) - GlaxoSmithKline; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Effexor (Venlafaxine) - Wyeth; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Remeron/Zispin (Mirtazapine) - Organon/Akzo Nobel; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Cipramil/Celexa (Citalopram) - Lundbeck/Forest Laboratories; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Cipralex/Lexapro (Escitalopram) - Lundbeck/Forest; Product Overview; Indications and Supplementary Labelling; Patent Expiry and Reformulation; Sales Prospects; Commercial Outlook; Future Considerations and Market Insights for the Antidepressant Market; Pipeline Antidepressants; Pipeline Focus; Valdoxan (Agomelatine) - Servier; Pharmacotherapeutics for Cognitive Impairment and /Memory Deficits; Future Market Focus - Age-Related Cognitive Decline; Nootropil (Piracetam) - UCB Pharma; Companies Developing Drugs for Cognitive and Memory Impairment; EGb 761/Tanakan - Ipsen
Chapter 3 Drugs in Research and Development: Pipeline Mood Stabilizers and Drugs for Cognitive Impairment; Drugs in Development for Mood Disorders: Antidepressants and Anxiolytics; Depression and Anxiety: Research and Development Overview; Drugs in Development for Cognitive and Memory Impairment; Cognitive/Memory Impairment - Research and Development Overview
Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining: Data Analysis, Therapy Forecasting, and Prospect Mining; Market Analysis and Therapy Forecasting; Antidepressants and Anxiolytics; Therapy Area Forecasts; Comparative Analysis: Antidepressant/Anxiolytic Product Sales; Prospect Mining; Mood Disorders: Depression and Anxiety; Cognitive and Memory Impairment; Therapy Area Forecasts, 2012 and 2020
Chapter 5 Report Synopsis: Depressive/Anxiety and Cognitive/Memory Impairment - Key Data Points; Bibliography and Reference Sources
List of Tables: Table 1.1 Role of Neurotransmitters in Depression; Table 1.2 Symptoms of Depression and Bipolar Disorder/Mania; Table 1.3 Major Anxiety Disorders; Table 1.4 Causes of Dementia; Table 2.1 Estimated Global Sales & Forecasts of Leading Antidepressants, 2004-2012 (US$m); Table 2.2 Estimated Annual Growth Rates of Leading Antidepressants (%), 2004-2012; Table 2.3 Leading Antidepressants Ranked by Sales, 2005 & 2012; Table 2.4 Primary and Secondary Indications for Antidepressants; Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Prozac, 2005-2012; Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Cymbalta, 2005-2012; Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Zoloft, 2005-2012; Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Seroxat/Paxil, 2005-2012; Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Wellbutrin, 2005-2012; Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Effexor, 2005-2012; Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Remeron, 2005-2012; Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Cipramil/Celexa, 2005-12; Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Cipralex/Lexapro, 2005-12; Table 2.14 Drugs in Development for Cognitive and Memory Impairment, 2005 (partial); Table 3.1 Drugs in Development for Depression and Anxiety, 2005; Table 3.2 Drugs in Development for Cognitive and Memory Impairment, 2005; Table 4.1 Global Drug Market for Antidepressants and Anxiolytics (US$m) 2004-2012; Table 4.2 Therapy Area Forecasts for the Global Mood Disorders and Cognitive Impairment Market Sectors, 2012 and 2020
List of Figures: Figure 2.1 Estimated Global Sales of Leading Antidepressants, 2005 & 2012; Figure 2.2 Estimated Market Share of Leading Antidepressants, 2005 & 2012; Figure 4.1 Therapy Area Forecasts for Antidepressants and Anxiolytics, 2005 & 2012 (US$m); Figure 4.2 Comparative Analysis of Leading Antidepressants and Anxiolytics 2004-2012; Figure 4.3 Key Antidepressant/Anxiolytic Prospects in the CNS Development Pipeline, 2005; Figure 4.4 Key Cognitive and Memory Impairment Prospects in the CNS Development Pipeline, 2005

Abstract

Examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012. Key factors discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified to buffer the decline include the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance. The report also evaluates the emerging market sector of cognitive and memory impairment and shows the extent of R&D activities within the field. Analysis of both sectors reveals candidates that have top-line earning prospects and also provides an insight into potential licensing or acquisition opportunities in promising psychopharmacotherapy market subsectors.

REPORT HIGHLIGHTS AND KEY FINDINGS

Pharmacotherapies indicated for mood disorders account for a market valued at US$17.4 billion, which is forecast to decrease 13.6% CAGR to US$15 billion by 2012
Critical analysis of depression, anxiety disorders, and cognitive and memory impairment
Review of epidemiological, aetiological, and therapeutic data for key therapy areas
Analysis of 10 marketed products and inclusion of 88 R&D candidates identified in preclinical to clinical stages of development for depressive illnesses and cognitive impairment
Sales estimates (US$) to 2012 for major therapy areas
Strategic insights for life-cycle optimization and product development
Critical evaluation of leading antidepressants
Emerging markets identified and sector analysis
Trend analysis of industry events and activities over past 2 years
Detailed R&D themes and clusters by therapy area
Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
High revenue-yielding prospects identified with projected sales estimations
R&D pipeline positioning for key therapy areas
Market insights for product development and drug promotion

REASONS TO PURCHASE THIS REPORT

Detailed survey and analysis of the current and future mood disorder market
Comprehensive update on key marketed products indicated for depression and anxiety disorders
Review of epidemiological, demographic, aetiological, and therapeutic data associated with mood disorders and cognitive impairment
Market analysis and insight of key therapy areas and pipelines
Market value predictions of individual marketed products to 2012
Insight and trend analysis of pipeline products for depressive illnesses and cognitive and memory impairment
Review of promising pipeline products and potential market opportunities
Insight into potential blockbusters in the mood disorder and cognitive impairment therapy areas
Illustrates unmet needs of current pharmacotherapies to treat mood disorders and the underserved area of cognitive impairment
Provides extensive coverage of the R&D pipeline of key players in the depression/anxiety disorders and cognitive/memory impairments
Illustrates potential high-revenue earning prospects that are differentiated by novel indications or mechanism of action
Provides leads for potential licensing opportunities

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/13/2012 - 31

Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012

Table of Contents

Abstract